Final survival and safety results from a multicenter, open‐label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer
- 25 April 2008
- Vol. 112 (12), 2749-2755
- https://doi.org/10.1002/cncr.23490
Abstract
BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth factor receptor (EGFR) with a proven survival advantage for patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) who have failed a prior chemotherapy. This phase 3b, multicenter, open‐label trial of erlotinib in patients with advanced NSCLC who had progressed after standard chemotherapy treatment was conducted to examine the efficacy and safety of erlotinib monotherapy in patients with advanced NSCLC who had developed disease progression after previous chemotherapy and to characterize the duration of survival and the response rate of erlotinib‐treated patients in subpopulations defined by other patient characteristics before U.S. Food and Drug Administration approval. METHODS. A total of 229 patients were enrolled and treated with the standard dose of erlotinib (150 mg once daily). The coprimary objectives were to characterize the overall response rate (ORR) and overall survival (OS) associated with erlotinib therapy in this group and in patient subsets defined by tobacco history. Secondary objectives were to assess safety, to characterize OS and ORR in patient subpopulations, and to determine duration of time on treatment. Patients could remain on study up to 9 months after approval. RESULTS. The ORR was 8.3% (95% confidence interval [95% CI], 5.2–2.4%). The ORR in never‐smokers, previous smokers, and current smokers was 28.6% (95% CI, 13.2–50.6%), 6.0% (95% CI, 3.0–10.4%), and 7.3% (95% CI, 2.0–19.0%), respectively. The median OS for all patients was 6.3 months (95% CI, 4.7–8.0 months). In previous and current smokers, the median survival was 5.2 months (95% CI, 4.2–7.3 months) and 6.3 months (95% CI, 3.6–9.2 months), respectively, and was not reached in never‐smokers. The median duration of treatment was 10.6 weeks. One (0.4%) interstitial lung disease‐like event was reported. CONCLUSIONS. No new safety signals were noted. The observed ORR and survival data are consistent with results from the pivotal trial BR.21. Cancer 2008. © 2008 American Cancer Society.This publication has 12 references indexed in Scilit:
- Epidermal Growth Factor Receptor Targeting in CancerSeminars in Oncology, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor ReceptorCancer Research, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2005
- Treatment approaches in patients with advanced non-small cell lung cancer and poor performance statusSeminars in Oncology, 2004
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003Journal of Clinical Oncology, 2004
- Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckJournal of Clinical Oncology, 2004
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2The New England Journal of Medicine, 2001
- New aspects in the staging of lung cancer. Prospective validation of the international union against cancer TNM classificationCancer, 1992